Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market – Industry Trends and Forecast to 2030

Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, By Type (VEGF-A Inhibitor, VEGF-B Inhibitor, VEGF-C Inhibitor, VEGF-D Inhibitor), Application (Oncology, Ophthalmology, Others), Drugs Type (Avastin, Tecentriq, Cometriq, Eylea, Others), Route of Administration (Oral, Injectable, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.

Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Analysis and Size

The vascular endothelial growth factor (VEGF) inhibitor market is projected to witness huge growth during the forecast period. According to several reports, age-related macular degeneration affects around 8-7% of the global population, and 196 million individuals in 2020 and increasing to 288 million by 2040. Major market players operating in the industry are undergoing numerous collaborations and partnerships to increase their product portfolio by developing varied new products.

Data Bridge Market Research analyses a growth rate in the vascular endothelial growth factor (VEGF) inhibitor market in the forecast period 2023-2030. The expected CAGR of vascular endothelial growth factor (VEGF) inhibitor market is tend to be around 10.7% in the mentioned forecast period. The market was valued at USD 8.27 billion in 2022, and it would grow upto USD 18.65 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Scope and Segmentation

Market Definition

Vascular endothelial growth factor (VEGR) is a type of protein that causes formation of new blood vessels by triggering pre-existing blood vessels. The abnormal activity of VEGR leads to angiogenesis and could result in cancer formation. Its effects are high in ovarian and cervical cancer. The major types of vascular endothelial growth factor (VEGF) inhibitors are Avastin, tecentriq, cometriq, eylea, and others.

Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Dynamics

Drivers

• Increased Collaborations and Partnerships

There have been increasing partnerships between several market players that have led to the growth of the market. For instance, in May 2020, AbbVie, which is a US-based biopharmaceutical company acquired Allergan, Inc., a US-based pharmaceutical company that focused on eye care. This acquisition creates a biopharma firm with leadership roles in vital therapeutic areas such as immunology, hematologic oncology, Allergan Aesthetics, and neuroscience.

• Increased Prevalence of Cancer

According to the reports of the National Cancer Institute, around 1,685,210 new cases of cancer was detected in 2016 in the U.S alone. The most common types of cancer are colon and rectum, leukemia, prostate, breast, lung, bronchus, melanoma, kidney and renal pelvis, and pancreatic cancer. Thus, all these factors boost the growth of the market.

Opportunities

• Growing Research Activities

There has been numerous research activities associated with the drugs that lead to the market expansion. For instance, in April 2018, Molecular Partners, Switzerland based biopharmaceutical company, collaborated with U.K. based pharmaceutical AstraZeneca, for the trial of its oncology candidate MP0250 with AstraZeneca’s antineoplastic agent osimertinib (Tagrisso) in Phase Ib/II studies. MP0250 will help prevent tumor growth by inhibiting two growth factors, hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF).

• Increasing Drug Approvals

More and more drugs are getting approved for treating patients with serious tumor growth. For instance, in April 2020, Bayer AG received approval from the European Medicines Agency (EMA) for its new Eylea (aflibercept) injection pre-filled syringe that will provide ophthalmologists with a more efficient and convenient way to administer EYLEA across all approved indications. The pre-filled syringe is convenient to prepare than the intravitreal injection procedure of the existing vial.

 Restraints/Challenges

• Side Effects of Renal Drugs

The side effects associated with these inhibitors could limit the growth of the market over a forecast period. Different side effects are associated with these inhibitors such as hypertension, stroke or heart attack, reversible posterior leukoencephalopathy syndrome, impaired wound healing, and protein in the urine. For instance, Bevacizumab, which is a FDA approved biosimilar drug, has side effects such as hypertension, bleeding, impaired wound healing, and gastrointestinal perforations

This vascular endothelial growth factor (VEGF) inhibitor market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the vascular endothelial growth factor (VEGF) inhibitor market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Scope

The vascular endothelial growth factor (VEGF) inhibitor market is segmented on the basis of type, application, drug type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• VEGF-A Inhibitor
• VEGF-B Inhibitor
• VEGF-C Inhibitor
• VEGF-D Inhibitor

Application

• Oncology
• Ophthalmology
• Others

Drugs Type

• Avastin
• Tecentriq
• Cometriq
• Eylea
• Others

Route of Administration

• Oral
• Injectable
• Others

End User        

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Regional Analysis/Insights

The vascular endothelial growth factor (VEGF) inhibitor market is analyzed and market size insights and trends are provided by type, application, drug type, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the vascular endothelial growth factor (VEGF) inhibitor market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing a highest growth for vascular endothelial growth factor (VEGF) inhibitor market throughout the forecasted period due to the high prevalence of cancer in the region.

North America dominates the market due to the well-structured healthcare system within the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Share Analysis

The vascular endothelial growth factor (VEGF) inhibitor market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to vascular endothelial growth factor (VEGF) inhibitor market.

Key players operating in the vascular endothelial growth factor (VEGF) inhibitor market include:

• Pfizer Inc (U.S.)
• AstraZeneca (U.K.)
• Bristol-Myers Squibb Company (U.S.)
• Teva Pharmaceutical Industries Ltd (Israel)
• Novartis AG (Switzerland)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Abbott (U.S.)
• Bayer AG (Germany)
• Sanofi (France)
• Eisai Inc. (U.S.)
• Merck & Co., Inc. (U.S.)
• Regeneron Pharmaceuticals Inc (U.S.)
• Exelixis, Inc. (U.S.).
• Genentech, Inc (U.S.)
• Boehringer Ingelheim International GmbH. (Germany)
• Mylan N.V. (U.S.)
• Abbvie, Inc (U.S.)
• CLOVIS ONCOLOGY (U.S.)
• AVEO Pharmaceuticals, Inc (U.S.)